157 related articles for article (PubMed ID: 21964530)
1. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
[TBL] [Abstract][Full Text] [Related]
2. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
4. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
5. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Laack E; Köhler A; Kugler C; Dierlamm T; Knuffmann C; Vohwinkel G; Niestroy A; Dahlmann N; Peters A; Berger J; Fiedler W; Hossfeld DK
Ann Oncol; 2002 Oct; 13(10):1550-7. PubMed ID: 12377642
[TBL] [Abstract][Full Text] [Related]
7. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
8. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Choi JH; Kim HC; Lim HY; Nam DK; Kim HS; Yi JW; Chun M; Oh YT; Kang S; Park KJ; Hwang SC; Lee YH; Hahn MH
Lung Cancer; 2001; 33(2-3):171-9. PubMed ID: 11551412
[TBL] [Abstract][Full Text] [Related]
10. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
11. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Edelman MJ; Wang X; Hodgson L; Cheney RT; Baggstrom MQ; Thomas SP; Gajra A; Bertino E; Reckamp KL; Molina J; Schiller JH; Mitchell-Richards K; Friedman PN; Ritter J; Milne G; Hahn OM; Stinchcombe TE; Vokes EE;
J Clin Oncol; 2017 Jul; 35(19):2184-2192. PubMed ID: 28489511
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
[TBL] [Abstract][Full Text] [Related]
14. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1229-1236. PubMed ID: 32152703
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
[TBL] [Abstract][Full Text] [Related]
18. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
20. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Mihaylova Zh; Ludovini V; Gregorg V; Floriani I; Pistola L; Toffaneti F; Ferraldeschi M; Spreafico A; Ceresoli GL; Bellet M; Darwish S; Tonato M; Raynov J
J BUON; 2007; 12(1):105-11. PubMed ID: 17436410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]